350 rub
Journal Technologies of Living Systems №1 for 2015 г.
Article in number:
Relationship between immunophenotype of diffuse large b-cell lymphoma with peculiarities of hematopoiesis in patients
Keywords: diffuse large B-cell lymphoma bone marrow myelogram blast cells elevated orthochromic normoblasts CD21 CD23 CD45 CD38 CD30
Authors:
P.A. Zeinalova - Ph.D. (Med.), Senior Research Scientist, Federal State Budgetary Scientific Institution «N.N. Blokhin Russian Cancer Research Center», Moscow E.N. Sholokhova - Ph.D. (Med.), Senior Research Scientist, Federal State Budgetary Scientific Institution «N.N. Blokhin Russian Cancer Research Center», Moscow M.A. Frenkel - Dr. Sc. (Med.), Professor, Leading Research Scientist, Federal State Budgetary Scientific Institution «N.N. Blokhin Russian Cancer Research Center», Moscow E.A. Osmanov - Dr. Sc. (Med.), Professor, Federal State Budgetary Scientific Institution «N.N. Blokhin Russian Cancer Research Center», Moscow N.N. Tupitsyn - Dr. Sc. (Med.), Professor, Federal State Budgetary Scientific Institution «N.N. Blokhin Russian Cancer Research Center», Moscow
Abstract:
There were some associations of bone marrow peculiarities, such as increase in percentage of blast cells (>=1%), changes in granulocytic differentiation, as well as the increase of percentage of ortochromic normoblasts with the overall survival in DLBCL patients (n = 118). In that patients we-ve studied the expression in primary tumor of HLA-DR, CD38, CD23, CD21, CD10, CD30, T-cell (CD3, CD5, CD7), macrophage (CD163), plasmacytic (CD38++) infiltration and presense in tumor sec-tions of 2 types of follicular dendritic cells (CD21, CD23). Level of blast cells was associated with CD21 expression. Decrease in percentage of segmented neutrophils was associated with CD45, CD38 and presence of CD23 follicular dendritic cells in tumor sections. Elevation of orthochromic normoblast levels was never seen in patients with CD30 expression.
Pages: 63-68
References

 

  1. Adylov M.A., KHamzaliev B.KH. Izmenenie ehritrona pri dlitelnykh gemorragijakh // Laboratornoe delo. 1990. № 5. S. 24-26.
  2. Vladimirskaja E.B. Osnovy krovetvorenija. V kn. Geriatricheskaja gematologija / pod red. L.D. Grinshpuna, A.V. Pivnika // M. Medium. 2011. S. 21-44.
  3. Dolgikh T.JU., Domnikova N.P., Petrusenko E.E. i dr. Morfologicheskaja kharakteristika centralnogo zvena ehritrona pri agressivnykh i indolentnykh nekhodzhkinskikh limfomakh // Bjulljuten ehksperimentalnojj biologii i mediciny. 2011. T. 151. № 2. S. 224-228.
  4. Frenkel M.A. Issledovanie kostnogo mozga v onkologii // Immunologija gemopoehza. 2014.  T. 12. № 1-2. S. 18-41.
  5. Alizadeh A.A., Eisen M.B., Davis R.E., et al. Distinct types of diffuse large B-cell lymphoma identified by gene-expression profiling // Nature. 2000. V. 403. P. 503-511.
  6. Campbell J., Seymour J.F., Matthews J., et al. The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement // Eur. J. Haematol. 2006. V. 76. P. 473-480.
  7. Cheson B.D., Fisher R.I., Barrington S.F., et al. Recommendation for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano Classification // J. Clin. Oncol. 2014. V. 32. P. 3059-3067.
  8. Ghelmini M., Vitolo U., Kimbyz E., et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) // Ann. Oncol. 2013. V. 24. P. 561-576.
  9. Inaba T., Nishimura H., Saito J., et al. A case of CD45-negative diffuse large B-cell lymphoman in thyroid gland // Lab. Hem. 2008. V. 14. P. 12-14.
  10. Le Gouill S., Talmant P., Touzeau C., et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/cMYC rearrangement // Haematologica. 2007. V. 92. P. 1335-1342.
  11. Linderoth J., Jerkeman M., Cavalin-Stahl E., et al. Immunohistochemical expression of CD23 and CD40 may identify prognostically favourable subgroup of diffuse large B-cell lymphoma: A Nordic lymphoma group study // Clin. Cancer Res. 2003. V. 9. P. 722-728.
  12. Martelli M., Ferreri A.J.M., Agostinelli C., et al.Diffuse large B-cell lymphoma.//Critical reviews in oncology/hematology. 2013. V.87. P.146-171.
  13. Nath P., Bhattacharya S., Bharadwaj R. ALK-positive diffuse large B-cell lymphoma - unusual subtype of diffuse large B-cell lymphoma (DLBCL) // Lymphoma Chronic lymphocytic leuk. 2010. V. 2. P. 1-5.
  14. Rimsza L.M., Farinha P., Fuchs D.A., et al. HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen // Leuk. Lymphoma. 2007. V. 48. P. 542-546.
  15. Schuurman H.J., Huppes W., Verdonck L.F., et al. Immunophenotyping of non-Hodgkin-s lymphoma. Correlation with relapse-free survival // Am. J. Pathol. 1988. V. 131. P. 102-111.
  16. Slack J.W., Steidl C., Sehn L.N., Gascone R.D. CD30 expression in de novo diffuse large B-cell lymphoma: a population based study from British Columbia // Br. J. Haematol. 2014. Doi:10.1111/bjh.13085.
  17. Stein H., Warnke R.A., Chan W.C., et al.Diffuse large B-cell lymphoma not otherwise specified. In: WHO classification of tumours of haematopoietic and lymphoid tissues (Swerdlow S.H., Campo E., Harris N.L., et al. Eds) // WHO Press. 2008.  P. 233-237.